3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
8
Sarcoma
4
Lymphoid
4
Plasma cell
3
Other hematologic neoplasm
3
Head & Neck
3
CNS
3
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
Dermatologic
2
Genitourinary
1
Breast
1
Conditions
Neuroendocrine Tumors
143
Carcinoma, Neuroendocrine
56
Thyroid Cancer, Papillary
54
Pheochromocytoma
50
Thyroid Neoplasms
41
Paraganglioma
41
Pituitary Neoplasms
37
Adrenocortical Carcinoma
31
Neoplasms
30
Multiple Endocrine Neoplasia Type 1
29
Gastro-enteropancreatic neuroendocrine tumor
29
Thyroid Carcinoma, Anaplastic
23
Small Cell Lung Carcinoma
21
Lung Neoplasms
21
Carcinoid Tumor
20
Sarcoma
19
Breast Neoplasms
19
Neoplasm Metastasis
18
Carcinoma, Non-Small-Cell Lung
18
Adenoma, Islet Cell
18
Melanoma
17
Carcinoma, Hepatocellular
17
Prostatic Neoplasms
15
Pancreatic Neoplasms
15
Ovarian Neoplasms
15
Neuroblastoma
15
Colorectal Neoplasms
15
Carcinoma, Renal Cell
15
Adrenal Gland Neoplasms
15
Adenocarcinoma, Follicular
15
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Erdheim-Chester Disease
×
Endocrine
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled